Genbioma

Genbioma is a commercially oriented research and development (R&D) startup that specializes in creating innovative solutions for human health, particularly in the field of probiotics and other bioactive compounds. The company's primary clients are the dietary supplement and food industries. Genbioma operates in the rapidly growing market of microbiome science, which focuses on the study of microorganisms in a particular environment such as the human body.

The company's business model revolves around the development of proprietary, patented bacterial strains (WO 2021/123355) which are used to create nutritional supplements. These supplements are designed to provide probiotic and postbiotic ingredients, which are beneficial bacteria and their byproducts respectively, that promote good health. Genbioma's products are backed by strong scientific evidence, setting them apart in the market.

Genbioma generates revenue through the sale of these nutritional supplements and through strategic partnerships with private and public entities, including universities, industry, and research centers. These alliances help the company overcome research, development, and market challenges. Notably, the company has secured private investment from Clave Capital and strategic partnerships with pharmaceutical sector company CINFA and animal health and nutrition experts Pentabiol S.L. Genbioma also benefits from a research agreement with the Centre for Nutrition Research at the University of Navarra.

The company's team is composed of experts in health, biology, biochemistry, biotechnology, and food technology. They are dedicated to researching and developing probiotic bacteria for human health food applications, with a strong belief that probiotics and postbiotics are the future of health benefits.

Keywords: Probiotics, Postbiotics, Nutritional Supplements, Microbiome Science, Research and Development, Health Food Applications, Dietary Supplement Industry, Food Industry, Biotech Technology, Strategic Partnerships.